Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained ownership of the genetic-testing company through her nonprofit, TTAM Research Institute. Wojcicki’s group outbid Regeneron Pharmaceuticals on Friday, offering $305 million to acquire nearly all of 23andMe’s assets. These include its Personal Genome Service, research services, and its telehealth arm, Lemonaid Health.
Wojcicki’s Nonprofit Reclaims 23andMe in $305M Deal
Wojcicki stepped down as CEO after 23andMe filed for Chapter 11 bankruptcy in March. Regeneron initially won the asset auction with a $256 million bid. However, Wojcicki reopened the bidding, securing the rights to buy back her creation under the nonprofit TTAM—an acronym derived from the first letters of 23andMe .
“I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome,” Wojcicki said in a statement.
From $6B Valuation to Breach and Bankruptcy
23andMe became widely known for its at-home DNA kits, offering users confidential insight into ancestry and genetic health. 23andMe went public in 2021 and was once valued at \$6 billion.
But things took a downturn as it struggled to make steady profits and expand into therapies. Then in 2023, a major data breach hit nearly 7 million users, shaking customer trust. This led to serious privacy concerns.
Wojcicki’s TTAM acquisition includes vital intellectual property, customer data, and telehealth services, signaling her plans to revive the company under a nonprofit model that keeps its mission intact—supporting personal genomics and research.
The deal still awaits approval from the U.S. Bankruptcy Court for the Eastern District of Missouri, but it remains a major step toward preserving the brand’s legacy and data integrity .
